BLA 761432 · Merck Sharp Dohme
Enflonsia
Clesrovimab-Cfor · Solution · Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody
NovelPriority reviewCDER novel approval, Jun 9, 2025: To prevent respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants who are born during or entering their first RSV season
Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Jun 9, 2025
Approved uses
2
Original approval plus efficacy supplements
Registered trials
5
2 Phase 3, 0 recruiting
FAERS reports
13
2 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 14, 2026.
ENFLONSIA ™ is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants who are born during or entering their first RSV season. ENFLONSIA is a respiratory syncytial virus (RSV) F protein-directed fusion inhibitor indicated for the prevention of RSV lower respiratory tract disease in neonates and infants who are born during or entering their first RSV season. ( 1 )
Mechanism: ENFLONSIA is a monoclonal antibody with anti-RSV activity [see Clinical Pharmacology (12.4) ].
Therapeutic areas: Infectious disease and vaccines
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 14, 2026 Supplement 3 · Efficacy LetterLabel
- Jun 9, 2025 Original approval · Type 1 - New Molecular Entity · priority review NovelLetterLabelReview
1 products under this application
- ENFLONSIA · CLESROVIMAB-CFOR 105MG/0.7ML · INJECTION, SOLUTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Clesrovimab" as an intervention, any sponsor and status, largest first.
- Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04767373 · 3,632 participants · Start Apr 7, 2021 · Primary completion Jul 9, 2024
Drug: Clesrovimab; Placebo · For: Respiratory Syncytial Virus Infection
Sites: Dothan, Alabama; Fayetteville, Arkansas; Jonesboro, Arkansas · 217 sites in all
- Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04938830 · 1,003 participants · Start Nov 30, 2021 · Primary completion Apr 28, 2025
Drug: Clesrovimab; Palivizumab and 1 more · For: RSV Infection
Sites: Long Beach, California; Orange, California; Aurora, Colorado · 146 sites in all
- Safety, Tolerability, and Pharmacokinetics of Clesrovimab (MK-1654) in Infants (MK-1654-002)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT03524118 · 183 participants · Start Sep 20, 2018 · Primary completion Sep 14, 2022
Drug: Clesrovimab; Placebo · For: Respiratory Tract Infection; Respiratory Syncytial Virus
Sites: Aurora, Colorado; Homestead, Florida; Miami, Florida · 34 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04086472 · 80 participants · Start Oct 28, 2019 · Primary completion Mar 22, 2020
Drug: Clesrovimab; RSV-A Memphis 37b · For: Respiratory Syncytial Viruses
Sites: London, United Kingdom
- The EMBRACE Study: Enflonsia Monoclonal in Babies - RSV Antibody Concentration EvaluationNot yet recruiting
Emory UniversityAcademic, hospital or other
NCT07824167 · 24 participants (planned) · Start Nov 2026 · Primary completion Mar 2028
Drug: Clesrovimab · For: RSV Infection
Sites: Atlanta, Georgia
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- no adverse event5
- extra dose administered2
- injection site pain2
- injection site swelling2
- product administered to patient of inappropriate age2
- pyrexia2
- respiratory syncytial virus infection2
- bacterial test positive1
- blood culture positive1
- influenza1
- injection site mass1
- medication error1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2025 | 6 |
| 2026 | 7 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Clesrovimab for Prevention of RSV Disease in Healthy Infants.
Zar HJ, Simões EAF, Madhi SA, et al. · N Engl J Med 2025 · Clinical Trial, Phase II, Clinical Trial, Phase III
- Systematic Review of the Efficacy and Safety of RSV-Specific Monoclonal Antibodies and Antivirals in Development.
Sevendal ATK, Hurley S, Bartlett AW, et al. · Rev Med Virol 2024 · Systematic Review
- A Phase 1b/2a Trial of a Half-life Extended Respiratory Syncytial Virus Neutralizing Antibody, Clesrovimab, in Healthy Preterm and Full-term Infants.
Madhi SA, Simões EAF, Acevedo A, et al. · J Infect Dis 2025 · Randomized Controlled Trial, Clinical Trial, Phase II
- RSV prophylactics for pediatric populations: A product review and meta-analysis of real-world effectiveness.
Oliva IO, Oliveira CR · Hum Vaccin Immunother 2026 · Meta-Analysis, Review
- Clesrovimab in Infants at Increased Risk For Severe Disease During 2 RSV Seasons: A Randomized Clinical Trial.
Zar HJ, Bont LJ, Manzoni P, et al. · JAMA Pediatr 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
- Phase I open-label study of the respiratory syncytial virus monoclonal antibody clesrovimab: Safety and tolerability in healthy Chinese participants.
He Y, Zhao F, Yang X, et al. · Hum Vaccin Immunother 2025 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
Sponsor: Merck & Co.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.